National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
 
 
Results: 1 -10 of 229         results per page
View Search Criteria | Help With Results
Title 
Phase sort descending
Protocol IDs 
 
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

   
Phase IV

   
ADO-MM-PAL8
NCT00226473

 
 
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

   
Phase III, Phase II

   
CA184-025
NCT00162123

 
 
High-Dose Interferon alfa in Treating Patients With Stage II or Stage III Melanoma

   
Phase III

   
ECOG-1697
SWOG-E1697, CALGB-500103, CAN-NCIC-ME10, COG-E1697, E1697, NCT00003641, ME10

 
 
Adesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

   
Phase III

   
CCCGHS-NCI-T98-0085
NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682

 
 
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

   
Phase III

   
11718
NCT00111007

 
 
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

   
Phase III

   
MM-ADJ-5
NCT00226408

 
 
PegIntron vs IntronA in CMAJCC Stage II (EADO 2001/CMII Trial).

   
Phase III

   
9267-01
2001-034, NCT00221702

 
 
Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage

   
Phase III

   
05 DIVE 03
NCT00224744

 
 
Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma

   
Phase III

   
BRD/04/1-D
NCT00200577

 
 
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

   
Phase III

   
NCI-06-C-0088
NCI-P6701, NCT00324727

 
      1 2 3 4   Next >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov